These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 25887498)
21. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373 [TBL] [Abstract][Full Text] [Related]
22. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. Meulenbeld HJ; Bleuse JP; Vinci EM; Raymond E; Vitali G; Santoro A; Dogliotti L; Berardi R; Cappuzzo F; Tagawa ST; Sternberg CN; Jannuzzo MG; Mariani M; Petroccione A; de Wit R BJU Int; 2013 Jan; 111(1):44-52. PubMed ID: 22928785 [TBL] [Abstract][Full Text] [Related]
23. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036 [TBL] [Abstract][Full Text] [Related]
24. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Cohen MH; Johnson JR; Pazdur R Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study. Schöffski P; Besse B; Gauler T; de Jonge MJ; Scambia G; Santoro A; Davite C; Jannuzzo MG; Petroccione A; Delord JP Ann Oncol; 2015 Mar; 26(3):598-607. PubMed ID: 25488684 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Chahardouli B; Zaker F; Mousavi SA; Kazemi A; Ostadali M; Nadali F; Rostami S; Alimoghaddam K; Ghavamzade A Hematology; 2013 May; 18(3):158-62. PubMed ID: 23540562 [TBL] [Abstract][Full Text] [Related]
27. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Swords R; Alvarado Y; Giles F Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S113-9. PubMed ID: 17382020 [TBL] [Abstract][Full Text] [Related]
28. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Kantarjian HM; O'Brien S; Cortes JE; Smith TL; Rios MB; Shan J; Yang Y; Giles FJ; Thomas DA; Faderl S; Garcia-Manero G; Jeha S; Wierda W; Issa JP; Kornblau SM; Keating M; Resta D; Capdeville R; Talpaz M Clin Cancer Res; 2002 Jul; 8(7):2167-76. PubMed ID: 12114417 [TBL] [Abstract][Full Text] [Related]
29. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation. Okabe S; Tauchi T; Ohyashiki K Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447 [TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749 [TBL] [Abstract][Full Text] [Related]
31. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [TBL] [Abstract][Full Text] [Related]
36. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454 [TBL] [Abstract][Full Text] [Related]
37. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome. Rabenau KE; Dolan M; Yohe S; Ustun C Cancer Genet; 2014 Mar; 207(3):109-10. PubMed ID: 24703333 [No Abstract] [Full Text] [Related]
39. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742 [TBL] [Abstract][Full Text] [Related]